סך נכסי הפעילות העסקית Protagenic (PTIX)

Protagenic Therapeutics specializes in developing innovative peptides for the treatment of major depressive disorder, wielding significant market influence due to the uniqueness of the PT00114 drug. This chart of stock quotes demonstrates total assets, which currently stand at 3.23. However, the company remains in a pre-commercial stage, rapidly burning through cash on costly trials, which creates a dependency on new equity offerings.

For the biotech startup Protagenic Therapeutics (PTIX), which is developing unique peptide treatments for depression, total resource value serves as a key indicator of financial stability. This metric, reverse-engineered via return on assets (ROA), determines the volume of assets and liabilities, allowing for an assessment of the balance between capital security and R&D efficiency by monitoring total balance sheet assets on GURU.Markets.